Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 5.17 -0.05 (0.96%)
Day High: 5.28
Day Low:  5.13
Volume:    78,267
10:56 AM ET
Feb 23, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Nov 15, 2016 / 3:00 PM ET
Aug 24, 2016 / 3:30 PM CT